C07K 16/3084
Against tumour-associated gangliosides
Official title: {against tumour-associated gangliosides}
C07K16/3084 (Against tumour-associated gangliosides) appears on 205 US grants and 409 published applications in this corpus.
Search patents in C07K- Granted patents
- 205
- Published applications
- 409
- Assignees
- 204
- Inventors
- 708
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 4 | 3 |
| 2003 | 2 | 8 |
| 2004 | 0 | 5 |
| 2005 | 4 | 12 |
| 2006 | 3 | 9 |
| 2007 | 3 | 14 |
| 2008 | 3 | 5 |
| 2009 | 3 | 13 |
| 2010 | 20 | 21 |
| 2011 | 3 | 6 |
| 2012 | 12 | 7 |
| 2013 | 8 | 6 |
| 2014 | 6 | 12 |
| 2015 | 7 | 11 |
| 2016 | 7 | 17 |
| 2017 | 9 | 13 |
| 2018 | 9 | 22 |
| 2019 | 8 | 24 |
| 2020 | 11 | 20 |
| 2021 | 13 | 33 |
| 2022 | 12 | 22 |
| 2023 | 15 | 30 |
| 2024 | 7 | 42 |
| 2025 | 18 | 30 |
| 2026 | 9 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- Methods of treating paraproteinemic neuropathy with anti-C2 antibodies18 Aug 2026US 12,708,664 B2argenx BV
- Engineered IgA antibodies and methods of use19 May 2026US 12,630,650 B2TigaTX, Inc.
- Glypican-2-binding moieties, chimeric antigen receptors and uses thereof21 Apr 2026US 12,606,635 B2Nanjing Legend Biotech Co., Ltd.
- Methods for treating neuroblastoma24 Mar 2026US 12,582,625 B2Arizona Board of Regents on Behalf of the University of Arizona
- Method for the production of bi-functional cells to treat neoplasia1 Oct 2026US 2026/0297162 A1Eir Biotherapies Srl
- SIRPalpha Knockout iPSC-derived and CAR-comprising Macrophages with Enhanced Anti-tumor Activity24 Sep 2026US 2026/0284104 A1Wisconsin Alumni Research Foundation
- Gd2-specific chimeric antigen receptor effector cells for use in the treatment of solid tumors, possibly in combination with enhancer of zeste homolog 2 (ezh2) inhibitors10 Sep 2026US 2026/0265408 A1
- Microenvironment actuated t-cells and uses thereof20 Aug 2026US 2026/0242732 A1
- Methods and compositions for gene transduction and to control the activity of synthetic and immune receptors6 Aug 2026US 2026/0226133 A1Angeles Therapeutics, Inc.
Most cited
By later US patents
- Cells producing antibody compositions with increased antibody dependent cytotoxic activity247US 6,946,292 B2Kyowa Hakko Kogyo Co., Ltd. · 2005
- Method of modulating the activity of functional immune molecules146US 7,214,775 B2Kyowa Hakko Kogyo Co., Ltd. · 2007
- Multiple cytokine protein complexes145US 6,617,135 B1EMD Lexigen Research Center Corp. · 2003
- Process for producing humanized chimera antibody144US 5,866,692 AKyowa Hakko Kogyo Co., Ltd. · 1999
- Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods108US 6,451,995 B1Sloan-Kettering Institute for Cancer Research · 2002